trial · primary record
Asparaginase Erwinia chrysanthemi
B Acute Lymphoblastic Leukemia
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 6720 |
| Primary completion | 2027-09-30 |
| Primary endpoint | Disease free survival (DFS) in randomization eligible patients with higher risk features (SR-High) or standard risk average (SR-Avg) B-ALL patients based on randomization with addition of blinatumomab |
| Registry ID | NCT03914625 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:24.109Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03914625
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.